Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine

Kiyoharu Ukai, Terutake Nakagawa, Tadashi Ohyama, Hiroshi Nakanishi

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

In order to clarify the mechanism underlying the anti-obesity effects of sibutramine, we examined the effects of sibutramine on extracellular levels of dopamine and 5-hydroxytryptamine (5-HT) through microdialysis in the striatum in unanesthetized and freely moving rats. Sibutramine (5 mg/kg, oral administration (p.o.)) increased extracellular dopamine and 5-HT levels in rat striatum. The tricyclic antidepressant dosulepin (80 mg/kg, p.o. or 1 μM perfusion through the striatal probe) increased 5-HT levels only. Sibutramine-induced dopamine release was antagonized by perfusion of tetrodotoxin (1 μM) through the microdialysis probe in the striatum. However, sibutramine-induced dopamine release was not inhibited by prazosin (1 mg/kg, intraperitoneal injection (i.p.)), a suppressor of serotonergic activity in the striatum via blockade of α1-adrenoceptors, or perfusion with nomifensine (1 μM), an inhibitor of dopamine re-uptake. These results suggest that sibutramine increases dopamine levels in the striatum by exocytotic release and not by a carrier-mediated mechanism.

元の言語英語
ページ(範囲)209-215
ページ数7
ジャーナルEuropean Journal of Pharmacology
484
発行部数2-3
DOI
出版物ステータス出版済み - 1 26 2004

Fingerprint

sibutramine
Dopamine
Serotonin
Perfusion
Microdialysis
Dothiepin
Dopamine Uptake Inhibitors
Nomifensine
Corpus Striatum
Tricyclic Antidepressive Agents
Prazosin
Tetrodotoxin
Intraperitoneal Injections
Adrenergic Receptors
Oral Administration
Obesity

All Science Journal Classification (ASJC) codes

  • Pharmacology

これを引用

Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine. / Ukai, Kiyoharu; Nakagawa, Terutake; Ohyama, Tadashi; Nakanishi, Hiroshi.

:: European Journal of Pharmacology, 巻 484, 番号 2-3, 26.01.2004, p. 209-215.

研究成果: ジャーナルへの寄稿記事

Ukai, Kiyoharu ; Nakagawa, Terutake ; Ohyama, Tadashi ; Nakanishi, Hiroshi. / Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine. :: European Journal of Pharmacology. 2004 ; 巻 484, 番号 2-3. pp. 209-215.
@article{f0c5a4b904e343bd9b0d39addf320865,
title = "Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine",
abstract = "In order to clarify the mechanism underlying the anti-obesity effects of sibutramine, we examined the effects of sibutramine on extracellular levels of dopamine and 5-hydroxytryptamine (5-HT) through microdialysis in the striatum in unanesthetized and freely moving rats. Sibutramine (5 mg/kg, oral administration (p.o.)) increased extracellular dopamine and 5-HT levels in rat striatum. The tricyclic antidepressant dosulepin (80 mg/kg, p.o. or 1 μM perfusion through the striatal probe) increased 5-HT levels only. Sibutramine-induced dopamine release was antagonized by perfusion of tetrodotoxin (1 μM) through the microdialysis probe in the striatum. However, sibutramine-induced dopamine release was not inhibited by prazosin (1 mg/kg, intraperitoneal injection (i.p.)), a suppressor of serotonergic activity in the striatum via blockade of α1-adrenoceptors, or perfusion with nomifensine (1 μM), an inhibitor of dopamine re-uptake. These results suggest that sibutramine increases dopamine levels in the striatum by exocytotic release and not by a carrier-mediated mechanism.",
author = "Kiyoharu Ukai and Terutake Nakagawa and Tadashi Ohyama and Hiroshi Nakanishi",
year = "2004",
month = "1",
day = "26",
doi = "10.1016/j.ejphar.2003.11.023",
language = "English",
volume = "484",
pages = "209--215",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine

AU - Ukai, Kiyoharu

AU - Nakagawa, Terutake

AU - Ohyama, Tadashi

AU - Nakanishi, Hiroshi

PY - 2004/1/26

Y1 - 2004/1/26

N2 - In order to clarify the mechanism underlying the anti-obesity effects of sibutramine, we examined the effects of sibutramine on extracellular levels of dopamine and 5-hydroxytryptamine (5-HT) through microdialysis in the striatum in unanesthetized and freely moving rats. Sibutramine (5 mg/kg, oral administration (p.o.)) increased extracellular dopamine and 5-HT levels in rat striatum. The tricyclic antidepressant dosulepin (80 mg/kg, p.o. or 1 μM perfusion through the striatal probe) increased 5-HT levels only. Sibutramine-induced dopamine release was antagonized by perfusion of tetrodotoxin (1 μM) through the microdialysis probe in the striatum. However, sibutramine-induced dopamine release was not inhibited by prazosin (1 mg/kg, intraperitoneal injection (i.p.)), a suppressor of serotonergic activity in the striatum via blockade of α1-adrenoceptors, or perfusion with nomifensine (1 μM), an inhibitor of dopamine re-uptake. These results suggest that sibutramine increases dopamine levels in the striatum by exocytotic release and not by a carrier-mediated mechanism.

AB - In order to clarify the mechanism underlying the anti-obesity effects of sibutramine, we examined the effects of sibutramine on extracellular levels of dopamine and 5-hydroxytryptamine (5-HT) through microdialysis in the striatum in unanesthetized and freely moving rats. Sibutramine (5 mg/kg, oral administration (p.o.)) increased extracellular dopamine and 5-HT levels in rat striatum. The tricyclic antidepressant dosulepin (80 mg/kg, p.o. or 1 μM perfusion through the striatal probe) increased 5-HT levels only. Sibutramine-induced dopamine release was antagonized by perfusion of tetrodotoxin (1 μM) through the microdialysis probe in the striatum. However, sibutramine-induced dopamine release was not inhibited by prazosin (1 mg/kg, intraperitoneal injection (i.p.)), a suppressor of serotonergic activity in the striatum via blockade of α1-adrenoceptors, or perfusion with nomifensine (1 μM), an inhibitor of dopamine re-uptake. These results suggest that sibutramine increases dopamine levels in the striatum by exocytotic release and not by a carrier-mediated mechanism.

UR - http://www.scopus.com/inward/record.url?scp=1642464882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642464882&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2003.11.023

DO - 10.1016/j.ejphar.2003.11.023

M3 - Article

C2 - 14744605

AN - SCOPUS:1642464882

VL - 484

SP - 209

EP - 215

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -